KB072: A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Condition: Immune Thrombocytopenia

Sponsor: Kedrion S.p.A.

Full Title
Protocol KB072: A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Adult Patients with Chronic Immune Thrombocytopenia (ITP)

Study Treatment
KIg 10 Intravenous Human Normal Immunoglobulin (IVIg)

Eligibility/Info
Patients with chronic primary immune thrombocytopenia with a low platelet count on bloodwork. 

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage